News | August 12, 2024
Ami Organics reports Q1FY25 PAT lower 34% at Rs. 14.7 Cr
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
Revenue from operations stood at Rs. 313.4 crore during Q1 FY25
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
Revenue from Operations increased by 10.5% YoY to Rs. 7,567 crore with growth across the businesses
The inspection was concluded with zero observations
Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues
Our centers are performing as expected or even better
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
The EIR was issued post the last inspection of the facility conducted from May 6-10, 2024 which concluded with zero FDA 483 observations
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
Subscribe To Our Newsletter & Stay Updated
